文献速递消化道肿瘤与早癌消化内镜

内镜肌间剥离术治疗直肠深部黏膜下浸润癌:三年随访研究结果

Results of endoscopic intermuscular dissection for deep submucosal invasive rectal cancer: a three-year follow-up study.
PubMed 文献 · Gut · 2025-11-10

这项多中心研究分析了2019至2023年间两所学术中心连续前瞻性记录的内镜肌间剥离术(EID)治疗疑似直肠深部黏膜下浸润癌(D-SMIC)的病例,评估三年肿瘤学结局。188例中整块切除率94.1%、R0切除率82.5%;94例D-SMIC中低危35例、中危32例、高危27例,低危全部、中危72%、高危22%接受主动监测。三年局部区域复发低危7%(1/35)、中危13%(2/15),均成功挽救,无远处复发或癌特异性死亡;作者认为EID后主动监测或可为低中危患者提供替代根治性手术的选择。

要点

  • EID治疗疑似直肠D-SMIC的整块切除率94.1%、R0切除率82.5%。
  • D-SMIC主动监测者三年局部区域复发低危7%(1/35)、中危13%(2/15),均成功挽救。
  • 低、中、高危组最终二次直肠手术率分别为5.3%、25.0%、59.6%。

核心结论

  • 尽管术前准确分期存在挑战,EID后主动监测或可为低危和中危直肠D-SMIC患者提供替代根治性手术的可行选择,在多数病例中避免直肠手术并维持肿瘤学安全。

研究设计与样本

  • 多中心研究,分析两所学术中心2019至2023年间连续、前瞻性记录的疑似直肠D-SMIC(基于光学诊断)EID病例。
  • D-SMIC定义为黏膜下浸润深度sm2-sm3;组织学危险因素包括低分化肿瘤(G3)、淋巴血管侵犯、高级别肿瘤出芽及切缘阳性或不确定(R1/Rx)。
  • 纳入188例;采用Aalen-Johansen法估计累积发生率。

主要发现

  • 188例中EID整块切除率94.1%、R0切除率82.5%。
  • 177例完成操作者中16%为非浸润性组织学(低级别上皮内瘤变/高级别上皮内瘤变;20/177=11%)或浅层黏膜下浸润癌(sm1,9/177=5%),31%(54/177)为更深浸润(≥pT2)。
  • 剩余94例D-SMIC(53%)为主要目标人群:37%(n=35)低危(无组织学危险因素)、34%(n=32)中危(一个危险因素)、29%(n=27)高危(≥2个危险因素)。
  • 主动监测在所有低危患者、72%中危病例和22%高危组中启动;其余患者接受补充手术或辅助放化疗。
  • 三年时,主动监测的低危患者局部区域复发7%(1/35,95%CI 1%至28%),中危患者13%(2/15,95%CI 2%至35%),均成功挽救;监测中的6例高危患者中2例出现局部区域复发。

临床怎么用

  • 作者认为,EID后主动监测或可为低危和中危直肠D-SMIC患者提供替代根治性手术的可行选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoscopic intermuscular dissection (EID) is a promising new technique for managing rectal deep submucosal invasive cancer (D-SMIC), but long-term outcome data are currently lacking. OBJECTIVE: This multicentre study evaluated the three-year oncological outcomes of EID, focusing specifically on patients with rectal D-SMIC who underwent active surveillance following the procedure. DESIGN: Data from consecutive, prospectively recorded EID procedures for suspected rectal D-SMIC-based on optical diagnosis-performed at two academic centres between 2019 and 2023 were analysed. D-SMIC was defined as submucosal invasion of sm2-sm3 depth. Histological risk factors included poorly differentiated tumours (G3), lymphovascular invasion, high-grade tumour budding and positive or indeterminate resection margins (R1/Rx). Study outcomes included three-year rates of locoregional recurrence (intramural and nodal), distant recurrence (metastatic disease), non-salvageable recurrence, cancer-specific mortality and secondary rectal surgery. Cumulative incidence was estimated using the Aalen-Johansen method. RESULTS: Among the 188 included cases, EID achieved an en bloc resection rate of 94.1% and R0 resection rate of 82.5%, respectively. Of the 177 procedures that were completed, 16% showed non-invasive histology (low-grade dysplasia/high-grade dysplasia; 20/177=11%) or superficial submucosal invasive cancer (sm1, 9/177=5%), and 31% (54/177) showed deeper (≥pT2) invasion. The remaining 94 D-SMIC cases (53%) represented the main target group. Of these, 37% (n=35) were classified as low risk (no histological risk factors), 34% (n=32) as intermediate risk (one risk factor) and 29% (n=27) as high risk (≥2 risk factors). Active surveillance was initiated in all low-risk patients, in 72% of the intermediate-risk cases and in 22% of the high-risk group. The remaining patients underwent completion surgery or adjuvant chemoradiotherapy. At three years, locoregional recurrence occurred in 7% (1/35, 95% CI 1% to 28%) of low-risk and 13% (2/15, 95% CI 2% to 35%) of intermediate-risk patients managed with active surveillance. All were successfully salvaged. Among the six high-risk patients under surveillance, locoregional recurrence was seen in two. No distant recurrences or cancer-specific deaths occurred in any D-SMIC group. Secondary rectal surgery was finally performed in 5.3%, 25.0% and 59.6% of the low, intermediate and high-risk groups, respectively. CONCLUSION: Despite the challenges associated with accurate preoperative staging, EID followed by active surveillance may offer a viable alternative to radical surgery for patients with low- and intermediate-risk rectal D-SMIC, avoiding rectal surgery in most cases while maintaining oncological safety.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. van der Schee L, Albers SC, Didden P, et al. Results of endoscopic intermuscular dissection for deep submucosal invasive rectal cancer: a three-year follow-up study. Gut. 2025. PMID: 40562523. doi:10.1136/gutjnl-2024-334612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。